Analysts have revised their views on Autolus Therapeutics, with some changes occurring after the company launched Aucatyzl. The company is reportedly planning to cut its workforce while increasing manufacturing capacity. The impact of these developments and recent approvals on Autolus Therapeutics' valuation and long-term prospects is being evaluated.